A phase 3b, multicenter, open‐label, single‐arm study of roxadustat within a US dialysis organization: The DENALI study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 3b, multicenter, open‐label, single‐arm study of roxadustat within a US dialysis organization: The DENALI study
Authors
Keywords
-
Journal
Hemodialysis International
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-25
DOI
10.1111/hdi.13122
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
- (2023) David J. Jörg et al. PLoS Computational Biology
- Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease
- (2022) Henry H.L. Wu et al. Kidney Diseases
- Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
- (2022) Sishir Gang et al. AMERICAN JOURNAL OF NEPHROLOGY
- Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
- (2022) Tadao Akizawa et al. Clinical and Experimental Nephrology
- Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
- (2022) Steven Fishbane et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
- (2021) Steven Fishbane et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
- (2021) Lucia Del Vecchio et al. Journal of Clinical Medicine
- Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
- (2021) Volker H. Haase Kidney International Supplements
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
- (2021) Botond Csiky et al. ADVANCES IN THERAPY
- Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
- (2021) Jonathan Barratt et al. ADVANCES IN THERAPY
- Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD
- (2021) Robert Provenzano et al. Clinical Journal of the American Society of Nephrology
- Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
- (2021) Jonathan Barratt et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- COVID-19 Risk Factors and Mortality Outcomes Among Medicare Patients Receiving Long-term Dialysis
- (2021) Stephen Salerno et al. JAMA Network Open
- Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis
- (2020) Marie Evans et al. Clinical Kidney Journal
- Roxadustat for Chronic Kidney Disease-related Anemia in Non-dialysis Patients
- (2020) Daniel W. Coyne et al. Kidney International Reports
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
- (2019) Neil S. Sanghani et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial
- (2019) Francesco Locatelli et al. Clinical Journal of the American Society of Nephrology
- Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study
- (2019) Gunnar Toft et al. JOURNAL OF NEPHROLOGY
- Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
- (2019) Tadao Akizawa et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Association of Hemoglobin Concentration and Its Change With Cardiovascular and All‐Cause Mortality
- (2018) Gyeongsil Lee et al. Journal of the American Heart Association
- Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
- (2016) R. Provenzano et al. Clinical Journal of the American Society of Nephrology
- Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
- (2016) Ylenia Ingrasciotta et al. PLoS One
- Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
- (2016) Daniel Eriksson et al. BMC Nephrology
- Prevalence of Anemia in Chronic Kidney Disease in the United States
- (2014) Melissa E. Stauffer et al. PLoS One
- Transfusion Burden among Patients with Chronic Kidney Disease and Anemia
- (2010) E. V. Lawler et al. Clinical Journal of the American Society of Nephrology
- Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management
- (2009) Mehmet Kanbay et al. BLOOD PURIFICATION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started